# The impact of immune cells selection on the therapeutic efficacy of CAR-T cell therapy

## TL;DR

This paper explores how selecting specific immune cells can improve the effectiveness of CAR-T cell therapy for cancer treatment.

## Contribution

The study highlights novel immune cell sources and strategies to enhance CAR-T cell efficacy and reduce side effects.

## Key findings

- CAR-T cells derived from umbilical cord blood and induced pluripotent stem cells show enhanced tumor-killing ability.
- Using virus-specific T cells and γδT cells helps reduce graft-versus-host disease in CAR-T therapy.
- Blocking T cell exhaustion through immune checkpoint inhibitors improves CAR-T cell performance.

## Abstract

从免疫细胞层面总结了各种新型嵌合抗原受体T细胞（CAR-T细胞）疗法，健康年轻受试者的T细胞、干性记忆样T细胞、人体诱导多能干细胞、脐带血T细胞来源的CAR-T细胞疗法可增强肿瘤杀伤效应。从通用型CAR细胞方面，病毒特异性T细胞、γδT细胞、iNKT细胞、巨噬细胞等能有效减轻移植物抗宿主病反应。此外，增强去白细胞过程中单核细胞的清除、保持CD4+/CD8+ T细胞均衡比例等策略也是增强CAR-T细胞扩增及杀伤效力的方法。细胞耗竭标志物高表达的T细胞对CAR-T细胞的转导、扩增及发挥杀伤效力等会产生负向影响，使用免疫检查点阻断剂等方式抑制T细胞耗竭能提高CAR-T细胞作用效应。